Effects of Anticoagulants on Thrombolysis Mediated by Tissue Plasminogen Activator in Experimental Thrombosis Model
Tissue plasminogen activator (t-PA) is being used as thrombolytic therapy for patients with acute myocardial infarction , given in combination with anticoagulants such as heparin or warfarin. We compared the effects of the new selective thrombin inhibitors, argatroban and hirudin, with those of heparin, on the thrombolysis mediated by t-PA in an experimental model of thrombosis using the hamster cheek pouch.
KeywordsThrombolytic Therapy Subclavian Artery Tissue Plasminogen Activator Unfractionated Heparin Fibrinolytic System
Unable to display preview. Download preview PDF.
- 4.Gaffney PJ, Marsh NA, Thomas DP. (1982) The influence of heparin and heparin-like substances on the fibrinolytic system in vivo. Heamostasis 12: 85Google Scholar
- 6.Rosenberg RD. Heparin-antithrombin system. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsch J, Marder VJ, Salzman EW (eds). JP Lippincott, Philadelphia, PA 1987; pp 962–85Google Scholar
- 7.Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, Mineo K, Okamoto S. (1986) Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Heamostas 56: 29–34Google Scholar
- 9.Heras M, Chesebro JH, Penny WJ Bailey KR, Badimon L, Fuster V. (1989) Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79: 657–665PubMedCrossRefGoogle Scholar